Recommended Pages at abbott.com
Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company: March 21, 2012
abbott.com — “Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company: March 21, 2012” View full resource at abbott.com
Most Recently Shared on March 21, 2012 at 2:20 pm By:
eyeonfda Pharma and Health Lawyer
MT @abbottnews: #Abbott announces #AbbVie (pronounced Abb-vee) new name for future research-based pharma company $ABT http://t.co/Y4CJqo2t
Abbott Introduces the First FDA-Approved Supplemental Blood Test for Chagas Disease: November 21, 2011
abbott.com — “Abbott Introduces the First FDA-Approved Supplemental Blood Test for Chagas Disease: November 21, 2011” View full resource at abbott.com
Most Recently Shared on November 23, 2011 at 6:15 pm By:
Global Network Health Organization
New FDA-approved blood test for #Chagas will make for a more accurate diagnosis of the disease. http://t.co/7GoaIE0C #NTDs #LAC @PAHOWHO
Abbott Reports Five-Year Data for HUMIRA® (Adalimumab) in Ankylosing Spondylitis: November 8, 2011
abbott.com — “Abbott Reports Five-Year Data for HUMIRA® (Adalimumab) in Ankylosing Spondylitis: November 8, 2011” View full resource at abbott.com
Most Recently Shared on November 8, 2011 at 4:21 pm By:
Dr Irwin Lim Rheumatologist, Physician, Active Health Library, and Doctor
RT @AbbottNews: At #ACR2011 #Abbott $ABT presents compelling open-label extension data in Ankylosing Spondylitis http://t.co/bkKqSk7U
Abbott Presents HUMIRA® (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis: November 7, 2011
abbott.com — “Abbott Presents HUMIRA® (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis: November 7, 2011” View full resource at abbott.com
Most Recently Shared on November 7, 2011 at 6:40 pm By:
Dr Irwin Lim Rheumatologist, Physician, Active Health Library, and Doctor
Effective but surprised efficacy was not higher: HUMIRA in Non-radiographic Axial Spondyloarthritis #ACR2011 http://t.co/wE0wRDzn
Abbott Introduces New ALK Genetic Test for Specific Form of Non-Small-Cell Lung Cancer: August 30, 2011
abbott.com — “Abbott Introduces New ALK Genetic Test for Specific Form of Non-Small-Cell Lung Cancer: August 30, 2011” View full resource at abbott.com
Most Recently Shared on August 30, 2011 at 2:19 pm By:
eyeonfda Pharma and Health Lawyer
Abbott Introduces New ALK Genetic Test for Specific Form of Non-Small-Cell Lung Cancer http://t.co/ysOEePs
Biogen Idec And Abbott Announce Positive Top-Line Results
abbott.com — “Biogen Idec And Abbott Announce Positive Top-Line Results” View full resource at abbott.com
Most Recently Shared on August 9, 2011 at 1:59 pm By:
eyeonfda Pharma and Health Lawyer
Biogen Idec & Abbott announce topline Ph 2b results from daclizumab HYP trial 4 relapse-remitting multiple sclerosis - http://ow.ly/5YIqm
Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels: May 24, 2011
abbott.com — “Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels: May 24, 2011” View full resource at abbott.com
Most Recently Shared on May 25, 2011 at 2:47 pm By:
eyeonfda Pharma and Health Lawyer
Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels - http://ow.ly/52HIr
Abbott Completes Submission of New Molecular Test Intended for Non-small-cell Lung Cancer Therapy Selection: May 23, 2011
abbott.com — “Abbott Completes Submission of New Molecular Test Intended for Non-small-cell Lung Cancer Therapy Selection: May 23, 2011” View full resource at abbott.com
Most Recently Shared on May 23, 2011 at 4:06 pm By:
eyeonfda Pharma and Health Lawyer
Abbott Completes Submission of New Molecular Test Intended for Non-small-cell Lung Cancer Therapy Selection - http://ow.ly/50S4w
Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study: May 10, 2011
abbott.com — “Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study: May 10, 2011” View full resource at abbott.com
Most Recently Shared on May 10, 2011 at 7:20 pm By:
eyeonfda Pharma and Health Lawyer
Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study - http://ow.ly/4RvB8
New Fully Automated Vitamin D Assay Submitted for FDA Clearance: April 15, 2011
abbott.com — “New Fully Automated Vitamin D Assay Submitted for FDA Clearance: April 15, 2011” View full resource at abbott.com
Most Recently Shared on April 15, 2011 at 1:46 pm By:
eyeonfda Pharma and Health Lawyer
Abbott files for 510(k) clearance for the ARCHITECT 25-OH Vitamin D assay - http://ow.ly/4B0c9
Positive Results from Phase 2 Study of Atrasentan for Treatment of Diabetic Kidney Disease Published in the Journal of the American Society of Nephrology: March 4, 2011
abbott.com — “Positive Results from Phase 2 Study of Atrasentan for Treatment of Diabetic Kidney Disease Published in the Journal of the American Society of Nephrology: March 4, 2011” View full resource at abbott.com
Most Recently Shared on March 4, 2011 at 9:11 pm By:
Positive Results from Phase 2 Study of Atrasentan for Treatment of Diabetic Kidney Disease (Abbott) http://bit.ly/dUvg20
Abbott Labs: Global Health Care & Medical Research
abbott.com — “Abbott Labs: Global Health Care & Medical Research” View full resource at abbott.com
Most Recently Shared on September 23, 2010 at 9:31 pm By:
Pregnancy Magazine Health Magazine
Are you using a Similac formula? Better go check the recall list at Abbott Labs' website: http://bit.ly/9YG5qv
Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.: September 23, 2010
abbott.com — “Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.” View full resource at abbott.com
Most Recently Shared on September 23, 2010 at 1:14 pm By:
Lisa Jarvis Science Enthusiast
Abbott to pay up to $450m for Reata Pharma's bardoxolone (in PhII for chronic kidney disease): http://bit.ly/c0Q0oh $ABT
Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment: Setpember 1, 2010
abbott.com — “Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment” View full resource at abbott.com
Most Recently Shared on September 1, 2010 at 2:47 pm By:
eyeonfda Pharma and Health Lawyer
Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment - http://ow.ly/2xVMD
Abbott Receives FDA Clearance for Molecular Diagnostic Test for Detection of Chlamydia and Gonorrhea Infections: June 28, 2010
abbott.com — “Abbott Receives FDA Clearance for Molecular Diagnostic Test for Detection of Chlamydia and Gonorrhea Infections” View full resource at abbott.com
Most Recently Shared on June 28, 2010 at 2:40 pm By:
eyeonfda Pharma and Health Lawyer
Abbott Gets FDA Nod 4 Molecular Diagnostic Test 4 Detection of Chlamydia & Gonorrhea Infections http://ow.ly/24b3e
